NCT00568308View on ClinicalTrials.gov

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
CancerLiver CancerPrimary Liver CancerHepatocellular CarcinomaHepatoma
Interventions
DRUG

PI-88

160mg subcutaneous injection

DRUG

placebo

matched placebo

Trial Locations (10)

Unknown

United States of America

Australia

Canada

Hong Kong

Italy

Malaysia

Singapore

Spain

Dawan

Thailand

Sponsors
All Listed Sponsors
lead

Progen Pharmaceuticals

INDUSTRY